8.64
+0.09(+1.05%)
Currency In USD
| Previous Close | 8.55 |
| Open | 8.47 |
| Day High | 8.72 |
| Day Low | 8.32 |
| 52-Week High | 14.8 |
| 52-Week Low | 2.68 |
| Volume | 1.56M |
| Average Volume | 1.44M |
| Market Cap | 713.43M |
| PE | -2.51 |
| EPS | -3.44 |
| Moving Average 50 Days | 8.63 |
| Moving Average 200 Days | 7.81 |
| Change | 0.09 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $569.92 as of February 21, 2026 at a share price of $8.64. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $242.15 as of February 21, 2026 at a share price of $8.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management te
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
GlobeNewswire Inc.
Nov 07, 2025 9:45 PM GMT
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failureWOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncoly